ME00427B - N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze - Google Patents

N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze

Info

Publication number
ME00427B
ME00427B MEP-2008-637A MEP63708A ME00427B ME 00427 B ME00427 B ME 00427B ME P63708 A MEP63708 A ME P63708A ME 00427 B ME00427 B ME 00427B
Authority
ME
Montenegro
Prior art keywords
compounds
hiv
aids
onset
prevention
Prior art date
Application number
MEP-2008-637A
Other languages
English (en)
Inventor
Benedetta Irbm Crescenzi
Cristina Irbm Gardelli
Ester Irbm Muraglia
Emanuela Irbm Nizi
Federica Irbm Orvieto
Paola Irbm Pace
Giovanna Irbm Pescatore
Alessia Irbm Petrocchi
Marco Irbm Poma
Michael Irbm Rowley
Rita Irbm Scarpelli
Vincenzo Irbm Summa
Original Assignee
Msd Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00427(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Italia Srl filed Critical Msd Italia Srl
Publication of ME00427B publication Critical patent/ME00427B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Kao inhibitori HIV integraze i inhibitori replikacije HIV-a, opisani su N-supstituisani 5-hidroksipirimidin-6-on-4-karboksamidi sa formulom (l) u kojoj su R1, R2 , R3 i R4 ovde definisani. Ova jedinjenja su korisna u prevenciji i lečenju infekcija HIV-om i u prevenciji, odlaganju otpočinjanja i lečenju AIDS-a. Jedinjenja se koriste protiv HIV infekcije i AIDS-a kao jedinjenja per se ili u obliku farmaceutski prihvatljivih soli. Jedinjenja i njihove soli se mogu upotrebiti kao sastojci u farmaceutskim smešama, opciono u kombinaciji sa drugim antivirusnim lekovima, imunomodulatorima, antibioticima ili vakcinama. Postupci prevencije, lečenja ili odlaganja otpočinjanja AIDS-a i postupci za prevenciju ili lečenje infekcije HIV-om su, takođe, opisani. Kao inhibitori HIV integraze i inhibitori replikacije HIV-a, opisani su N-supstituisani 5-hidroksipirimidin-6-on-4-karboksamidi sa formulom (l) u kojoj su R1, R2 , R3 i R4 ovde definisani. Ova jedinjenja su korisna u prevenciji i lečenju infekcija HIV-om i u prevenciji, odlaganju otpočinjanja i lečenju AIDS-a. Jedinjenja se koriste protiv HIV infekcije i AIDS-a kao jedinjenja per se ili u obliku farmaceutski prihvatljivih soli. Jedinjenja i njihove soli se mogu upotrebiti kao sastojci u farmaceutskim smešama, opciono u kombinaciji sa drugim antivirusnim lekovima, imunomodulatorima, antibioticima ili vakcinama. Postupci prevencije, lečenja ili odlaganja otpočinjanja AIDS-a i postupci za prevenciju ili lečenje infekcije HIV-om su, takođe, opisani.
MEP-2008-637A 2001-10-26 2002-10-21 N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze ME00427B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33956801P 2001-10-26 2001-10-26
US36219102P 2002-03-06 2002-03-06
PCT/GB2002/004753 WO2003035077A1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase

Publications (1)

Publication Number Publication Date
ME00427B true ME00427B (me) 2011-10-10

Family

ID=26991691

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-637A ME00427B (me) 2001-10-26 2002-10-21 N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze

Country Status (35)

Country Link
US (5) US7169780B2 (me)
EP (1) EP1441735B1 (me)
JP (1) JP3927175B2 (me)
KR (1) KR100862879B1 (me)
CN (3) CN102229605B (me)
AT (1) ATE318140T1 (me)
BR (1) BRPI0213522C1 (me)
CA (1) CA2463976C (me)
CO (1) CO5580777A2 (me)
CY (1) CY2008008I1 (me)
DE (3) DE122008000016I1 (me)
DK (1) DK1441735T3 (me)
EA (1) EA007060B1 (me)
ES (1) ES2258668T3 (me)
FR (1) FR08C0026I2 (me)
GE (1) GEP20063848B (me)
HK (1) HK1085665A1 (me)
HR (1) HRP20040373B1 (me)
HU (2) HU230248B1 (me)
IL (2) IL161337A0 (me)
IS (1) IS2436B (me)
LT (1) LTC1441735I2 (me)
LU (1) LU91428I2 (me)
ME (1) ME00427B (me)
MX (1) MXPA04003932A (me)
NL (1) NL300340I2 (me)
NO (3) NO325206B1 (me)
NZ (1) NZ533057A (me)
PL (1) PL212914B1 (me)
PT (1) PT1441735E (me)
RS (1) RS51542B (me)
SI (1) SI1441735T1 (me)
UA (1) UA77454C2 (me)
WO (1) WO2003035077A1 (me)
ZA (1) ZA200402796B (me)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425440C (en) 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
AU2002246499B2 (en) 2000-10-12 2005-12-22 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
EP1422218B1 (en) 2001-08-10 2012-03-21 Shionogi & Co., Ltd. Antiviral agent
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
PT1441734E (pt) * 2001-10-26 2007-05-31 Isti Di Ric Di Bio Moleco P An Di-hidroxipirimidinocarboxamidas inibidoras da integrase do vih
EA007060B1 (ru) * 2001-10-26 2006-06-30 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
AU2003220170B2 (en) 2002-03-15 2008-12-11 Merck Sharp & Dohme Corp. N-(Substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as HIV integrase inhibitors
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
CA2483627A1 (en) * 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
DE60322919D1 (de) 2002-09-11 2008-09-25 Merck & Co Inc 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
CA2498111A1 (en) * 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
EP1578748B1 (en) * 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004062613A2 (en) * 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1870896A (zh) 2003-10-20 2006-11-29 默克公司 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
US20050090668A1 (en) * 2003-10-28 2005-04-28 Dreher Spencer D. Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
JP2007518711A (ja) 2003-12-19 2007-07-12 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
KR20060124701A (ko) * 2004-01-12 2006-12-05 길리애드 사이언시즈, 인코포레이티드 피리미딜 포스포네이트 항바이러스성 화합물 및 그의 사용방법
JP2007528396A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
WO2005092099A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. Hiv integrase inhibitors
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
WO2005087767A1 (en) * 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
WO2005110414A2 (en) * 2004-05-07 2005-11-24 Merck & Co., Inc. Hiv integrase inhibitors
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7173022B2 (en) * 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
JP2008521929A (ja) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド 抗核形成剤を含有する医薬組成物
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
BRPI0518781A2 (pt) * 2004-12-03 2008-12-09 Merck & Co Inc formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
MX2007006637A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
AU2006228278C1 (en) * 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
ES2437268T3 (es) 2005-04-28 2014-01-09 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
EP1881825B1 (en) 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
JP2009502964A (ja) * 2005-07-27 2009-01-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体
US7939537B2 (en) * 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
US20090312335A1 (en) * 2005-10-27 2009-12-17 John S Wai Hiv Integrase Inhibitors
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
AU2007275816A1 (en) * 2006-07-17 2008-01-24 Merck Sharp & Dohme Corp. 1-hydroxy naphthyridine compounds as anti-HIV agents
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
AU2007313293A1 (en) * 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
CN101206209B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析西多福韦原料及其制剂的方法
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
CN101801348A (zh) * 2007-06-22 2010-08-11 百时美施贵宝公司 含有阿扎那韦的压片组合物
CA2702317A1 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Novel pyrimidinecarboxamide derivatives
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
BRPI0821349A2 (pt) 2007-12-21 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
JP5564435B2 (ja) * 2008-01-08 2014-07-30 メルク・シャープ・アンド・ドーム・コーポレーション Ｎ−置換ヒドロキシピリミジノンカルボキサミドの製造方法
EP2247601B1 (en) * 2008-07-02 2013-04-10 Avexa Limited Thiazopyrimidinones and uses thereof
WO2010042391A2 (en) * 2008-10-06 2010-04-15 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2549387T3 (es) 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011003684A1 (en) * 2009-07-06 2011-01-13 Syngenta Participations Ag Insecticidal compounds
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
RS62600B1 (sr) 2009-10-26 2021-12-31 Merck Sharp & Dohme Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2011109261A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US9260413B2 (en) 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
US8969364B2 (en) 2010-03-04 2015-03-03 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
AU2011223969B2 (en) * 2010-03-04 2015-06-11 Merck Sharp & Dohme Llc Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
CA2999435A1 (en) * 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2011123754A1 (en) * 2010-04-01 2011-10-06 Teva Pharmaceutical Industries Ltd. Raltegravir salts and crystalline forms thereof
CN102917695A (zh) 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
US8962833B2 (en) 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
WO2012103105A1 (en) * 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012137142A1 (en) 2011-04-06 2012-10-11 Lupin Limited Novel salts of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) * 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
EP2529741B1 (en) 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
EP2804607B1 (en) * 2011-12-26 2020-09-16 Emcure Pharmaceuticals Limited Synthesis of raltegravir
AU2013213255A1 (en) 2012-01-25 2014-08-07 Lupin Limited Stable amorphous Raltegravir potassium premix and process for the preparation thereof
WO2014014933A1 (en) * 2012-07-20 2014-01-23 Merck Sharp & Dohme Corp. Hiv treatment with amido-substituted pyrimidinone derivatives
KR20150039832A (ko) * 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
CN102911124B (zh) * 2012-10-25 2015-11-25 山东大学 羟基嘧啶酮类化合物及其制备方法与应用
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
DK2997033T3 (da) 2013-05-17 2018-01-29 Merck Sharp & Dohme Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (me) 2013-07-12 2018-07-21
WO2015006731A1 (en) 2013-07-12 2015-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
EP3049081B1 (en) 2013-09-27 2019-11-27 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
WO2015114608A1 (en) 2014-02-03 2015-08-06 Mylan Laboratories Ltd Processes for the preparation of intermediates of raltegravir
CA2942239C (en) 2014-03-21 2020-09-22 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (me) 2014-06-20 2018-06-23
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US10259778B2 (en) 2014-11-10 2019-04-16 Aurobindo Pharma Ltd Process for the preparation of raltegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
CN107531727B (zh) 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2017220208A1 (en) 2016-06-21 2017-12-28 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
JP2019529410A (ja) 2016-09-15 2019-10-17 ルピン・リミテッド 純粋で安定な結晶のラルテグラビルカリウム３型の製造方法
KR20190086017A (ko) 2016-12-02 2019-07-19 머크 샤프 앤드 돔 코포레이션 Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
CA3080012A1 (en) 2017-11-14 2019-05-23 Cambrex Profarmaco Milano S.R.L. Process for the preparation of raltegravir
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687069T2 (de) 1985-03-16 1993-03-25 Wellcome Found Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5637618A (en) 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
DE4029654A1 (de) 1990-09-19 1992-04-02 Hoechst Ag 2-phenyl-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
TW287160B (me) 1992-12-10 1996-10-01 Hoffmann La Roche
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JP3794469B2 (ja) 1998-03-26 2006-07-05 塩野義製薬株式会社 抗ウイルス作用を有するインドール誘導体
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
EP1082121A4 (en) 1998-06-03 2003-02-05 Merck & Co Inc INTEGRASE HIV INHIBITORS
WO1999062897A1 (en) 1998-06-03 1999-12-09 Merck & Co., Inc. Hiv integrase inhibitors
MXPA01001843A (es) 1998-08-20 2002-04-08 Toyama Chemical Co Ltd Derivados de carboxamida heterociclica con nitrogeno o sales derivados de los mismos y agentes antivirales que comprenden los mismos.
AU763040B2 (en) 1998-12-25 2003-07-10 Shionogi & Co., Ltd. Aromatic heterocycle compounds having HIV integrase inhibiting activities
EP1159271B1 (en) 1999-03-04 2004-08-25 Korea Research Institute of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
CA2425440C (en) 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2425067A1 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
AU2002246499B2 (en) 2000-10-12 2005-12-22 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
IL157638A0 (en) 2001-03-01 2004-03-28 Shionogi & Co Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
EP1422218B1 (en) 2001-08-10 2012-03-21 Shionogi & Co., Ltd. Antiviral agent
EA007060B1 (ru) * 2001-10-26 2006-06-30 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
PT1441734E (pt) 2001-10-26 2007-05-31 Isti Di Ric Di Bio Moleco P An Di-hidroxipirimidinocarboxamidas inibidoras da integrase do vih
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP4059923A1 (en) 2002-11-20 2022-09-21 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors

Also Published As

Publication number Publication date
ATE318140T1 (de) 2006-03-15
IL161337A (en) 2010-02-17
HUS1600016I1 (hu) 2018-05-02
NL300340I1 (nl) 2008-06-02
NZ533057A (en) 2005-11-25
MXPA04003932A (es) 2004-06-18
NO2008007I1 (no) 2008-06-23
US20110034449A1 (en) 2011-02-10
CA2463976A1 (en) 2003-05-01
EA200400585A1 (ru) 2004-10-28
LU91428I2 (fr) 2008-06-09
IS7213A (is) 2004-04-07
CN1700918A (zh) 2005-11-23
DE122008000016I1 (de) 2011-12-01
CN102219750B (zh) 2013-05-29
BRPI0213522C1 (pt) 2021-05-25
HU230248B1 (hu) 2015-11-30
KR20040047981A (ko) 2004-06-05
LTC1441735I2 (lt) 2020-06-25
CO5580777A2 (es) 2005-11-30
HK1085665A1 (en) 2006-09-01
ZA200402796B (en) 2005-03-30
FR08C0026I2 (fr) 2010-01-22
DK1441735T3 (da) 2006-06-12
CN1700918B (zh) 2011-06-08
DE122009000048I1 (de) 2010-04-08
US20050025774A1 (en) 2005-02-03
NO2020026I1 (no) 2020-08-10
SI1441735T1 (sl) 2006-06-30
EA007060B1 (ru) 2006-06-30
US7169780B2 (en) 2007-01-30
UA77454C2 (en) 2006-12-15
ES2258668T3 (es) 2006-09-01
US20060258860A1 (en) 2006-11-16
BR0213522B8 (pt) 2017-07-04
IL161337A0 (en) 2004-09-27
NO20042165L (no) 2004-05-25
CN102229605B (zh) 2015-01-14
HUP0401740A2 (hu) 2004-12-28
AU2002334207B2 (en) 2006-02-23
BR0213522B1 (pt) 2017-06-13
DE60209381T2 (de) 2006-10-05
CA2463976C (en) 2007-02-13
CY2008008I1 (el) 2009-11-04
PL212914B1 (pl) 2012-12-31
HRP20040373B1 (en) 2012-09-30
PT1441735E (pt) 2006-06-30
DE60209381D1 (de) 2006-04-27
HRP20040373A2 (en) 2005-08-31
YU35604A (sh) 2006-08-17
EP1441735B1 (en) 2006-02-22
EP1441735A1 (en) 2004-08-04
CN102219750A (zh) 2011-10-19
JP2005511543A (ja) 2005-04-28
US20070123524A1 (en) 2007-05-31
US7217713B2 (en) 2007-05-15
IS2436B (is) 2008-10-15
US7820660B2 (en) 2010-10-26
HUP0401740A3 (en) 2009-06-29
JP3927175B2 (ja) 2007-06-06
NL300340I2 (nl) 2008-08-01
CN102229605A (zh) 2011-11-02
US7435734B2 (en) 2008-10-14
GEP20063848B (en) 2006-06-12
PL369223A1 (en) 2005-04-18
AU2002334207A2 (en) 2003-05-06
US20080275004A1 (en) 2008-11-06
KR100862879B1 (ko) 2008-10-15
RS51542B (sr) 2011-06-30
FR08C0026I1 (me) 2008-07-18
NO325206B1 (no) 2008-02-25
LTPA2008007I1 (lt) 2020-05-11
WO2003035077A1 (en) 2003-05-01
NO2008007I2 (me) 2010-09-27
BR0213522A (pt) 2004-09-08

Similar Documents

Publication Publication Date Title
ME00427B (me) N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
DK1441734T3 (da) Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
EA200300449A1 (ru) Аза- и полиаза-нафталинилкарбоксамиды, полезные в качестве ингибиторов вич-интегразы
ATE364385T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
ATE345129T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
ATE370948T1 (de) Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
ATE409187T1 (de) N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer
ATE404563T1 (de) 8-hydroxy-1- oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen